A multi-targeted approach to suppress tumor-promoting inflammation

Abbas K. Samadi, Alan Bilsland, Alexandros G. Georgakilas, Amedeo Amedei, Amr Amin, Anupam Bishayee, Asfar S. Azmi, Balakrishna L Lokeshwar, Brendan Grue, Carolina Panis, Chandra S. Boosani, Deepak Poudyal, Diana M. Stafforini, Dipita Bhakta, Elena Niccolai, Gunjan Guha, H. P. Vasantha Rupasinghe, Hiromasa Fujii, Kanya Honoki, Kapil MehtaKatia Aquilano, Leroy Lowe, Lorne J. Hofseth, Luigi Ricciardiello, Maria Rosa Ciriolo, Neetu Singh, Richard L. Whelan, Rupesh Chaturvedi, S. Salman Ashraf, H. M.C. Shantha Kumara, Somaira Nowsheen, Sulma I. Mohammed, W. Nicol Keith, William G. Helferich, Xujuan Yang

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes.

Original languageEnglish (US)
Pages (from-to)S151-S184
JournalSeminars in Cancer Biology
Volume35
DOIs
StatePublished - Dec 1 2015

Fingerprint

Inflammation
Neoplasms
Anti-Inflammatory Agents
Macrophage Migration-Inhibitory Factors
CXC Chemokines
Proto-Oncogene Proteins c-akt
Curcumin
Genetic Heterogeneity
Anthocyanins
Genistein
Nitric Oxide Synthase Type II
Drug Combinations
Cyclooxygenase 2
Therapeutics
Transcription Factors
Tumor Necrosis Factor-alpha
Phenotype
Costs and Cost Analysis
Recurrence

Keywords

  • Cancer
  • Hallmarks
  • Inflammation
  • Phytochemicals
  • Tumor

ASJC Scopus subject areas

  • Cancer Research

Cite this

Samadi, A. K., Bilsland, A., Georgakilas, A. G., Amedei, A., Amin, A., Bishayee, A., ... Yang, X. (2015). A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 35, S151-S184. https://doi.org/10.1016/j.semcancer.2015.03.006

A multi-targeted approach to suppress tumor-promoting inflammation. / Samadi, Abbas K.; Bilsland, Alan; Georgakilas, Alexandros G.; Amedei, Amedeo; Amin, Amr; Bishayee, Anupam; Azmi, Asfar S.; Lokeshwar, Balakrishna L; Grue, Brendan; Panis, Carolina; Boosani, Chandra S.; Poudyal, Deepak; Stafforini, Diana M.; Bhakta, Dipita; Niccolai, Elena; Guha, Gunjan; Vasantha Rupasinghe, H. P.; Fujii, Hiromasa; Honoki, Kanya; Mehta, Kapil; Aquilano, Katia; Lowe, Leroy; Hofseth, Lorne J.; Ricciardiello, Luigi; Ciriolo, Maria Rosa; Singh, Neetu; Whelan, Richard L.; Chaturvedi, Rupesh; Ashraf, S. Salman; Shantha Kumara, H. M.C.; Nowsheen, Somaira; Mohammed, Sulma I.; Keith, W. Nicol; Helferich, William G.; Yang, Xujuan.

In: Seminars in Cancer Biology, Vol. 35, 01.12.2015, p. S151-S184.

Research output: Contribution to journalReview article

Samadi, AK, Bilsland, A, Georgakilas, AG, Amedei, A, Amin, A, Bishayee, A, Azmi, AS, Lokeshwar, BL, Grue, B, Panis, C, Boosani, CS, Poudyal, D, Stafforini, DM, Bhakta, D, Niccolai, E, Guha, G, Vasantha Rupasinghe, HP, Fujii, H, Honoki, K, Mehta, K, Aquilano, K, Lowe, L, Hofseth, LJ, Ricciardiello, L, Ciriolo, MR, Singh, N, Whelan, RL, Chaturvedi, R, Ashraf, SS, Shantha Kumara, HMC, Nowsheen, S, Mohammed, SI, Keith, WN, Helferich, WG & Yang, X 2015, 'A multi-targeted approach to suppress tumor-promoting inflammation', Seminars in Cancer Biology, vol. 35, pp. S151-S184. https://doi.org/10.1016/j.semcancer.2015.03.006
Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A et al. A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology. 2015 Dec 1;35:S151-S184. https://doi.org/10.1016/j.semcancer.2015.03.006
Samadi, Abbas K. ; Bilsland, Alan ; Georgakilas, Alexandros G. ; Amedei, Amedeo ; Amin, Amr ; Bishayee, Anupam ; Azmi, Asfar S. ; Lokeshwar, Balakrishna L ; Grue, Brendan ; Panis, Carolina ; Boosani, Chandra S. ; Poudyal, Deepak ; Stafforini, Diana M. ; Bhakta, Dipita ; Niccolai, Elena ; Guha, Gunjan ; Vasantha Rupasinghe, H. P. ; Fujii, Hiromasa ; Honoki, Kanya ; Mehta, Kapil ; Aquilano, Katia ; Lowe, Leroy ; Hofseth, Lorne J. ; Ricciardiello, Luigi ; Ciriolo, Maria Rosa ; Singh, Neetu ; Whelan, Richard L. ; Chaturvedi, Rupesh ; Ashraf, S. Salman ; Shantha Kumara, H. M.C. ; Nowsheen, Somaira ; Mohammed, Sulma I. ; Keith, W. Nicol ; Helferich, William G. ; Yang, Xujuan. / A multi-targeted approach to suppress tumor-promoting inflammation. In: Seminars in Cancer Biology. 2015 ; Vol. 35. pp. S151-S184.
@article{fe698d940c054a6fbef5e6ecee7f5f72,
title = "A multi-targeted approach to suppress tumor-promoting inflammation",
abstract = "Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes.",
keywords = "Cancer, Hallmarks, Inflammation, Phytochemicals, Tumor",
author = "Samadi, {Abbas K.} and Alan Bilsland and Georgakilas, {Alexandros G.} and Amedeo Amedei and Amr Amin and Anupam Bishayee and Azmi, {Asfar S.} and Lokeshwar, {Balakrishna L} and Brendan Grue and Carolina Panis and Boosani, {Chandra S.} and Deepak Poudyal and Stafforini, {Diana M.} and Dipita Bhakta and Elena Niccolai and Gunjan Guha and {Vasantha Rupasinghe}, {H. P.} and Hiromasa Fujii and Kanya Honoki and Kapil Mehta and Katia Aquilano and Leroy Lowe and Hofseth, {Lorne J.} and Luigi Ricciardiello and Ciriolo, {Maria Rosa} and Neetu Singh and Whelan, {Richard L.} and Rupesh Chaturvedi and Ashraf, {S. Salman} and {Shantha Kumara}, {H. M.C.} and Somaira Nowsheen and Mohammed, {Sulma I.} and Keith, {W. Nicol} and Helferich, {William G.} and Xujuan Yang",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.semcancer.2015.03.006",
language = "English (US)",
volume = "35",
pages = "S151--S184",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A multi-targeted approach to suppress tumor-promoting inflammation

AU - Samadi, Abbas K.

AU - Bilsland, Alan

AU - Georgakilas, Alexandros G.

AU - Amedei, Amedeo

AU - Amin, Amr

AU - Bishayee, Anupam

AU - Azmi, Asfar S.

AU - Lokeshwar, Balakrishna L

AU - Grue, Brendan

AU - Panis, Carolina

AU - Boosani, Chandra S.

AU - Poudyal, Deepak

AU - Stafforini, Diana M.

AU - Bhakta, Dipita

AU - Niccolai, Elena

AU - Guha, Gunjan

AU - Vasantha Rupasinghe, H. P.

AU - Fujii, Hiromasa

AU - Honoki, Kanya

AU - Mehta, Kapil

AU - Aquilano, Katia

AU - Lowe, Leroy

AU - Hofseth, Lorne J.

AU - Ricciardiello, Luigi

AU - Ciriolo, Maria Rosa

AU - Singh, Neetu

AU - Whelan, Richard L.

AU - Chaturvedi, Rupesh

AU - Ashraf, S. Salman

AU - Shantha Kumara, H. M.C.

AU - Nowsheen, Somaira

AU - Mohammed, Sulma I.

AU - Keith, W. Nicol

AU - Helferich, William G.

AU - Yang, Xujuan

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes.

AB - Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes.

KW - Cancer

KW - Hallmarks

KW - Inflammation

KW - Phytochemicals

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84946186771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946186771&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2015.03.006

DO - 10.1016/j.semcancer.2015.03.006

M3 - Review article

C2 - 25951989

AN - SCOPUS:84946186771

VL - 35

SP - S151-S184

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -